Hannah Johnson Selected Research

Hannah Johnson Research Topics

Disease

11	Neoplasms (Cancer) 01/2024 - 08/2012
3	Inflammation (Inflammations) 12/2022 - 01/2021
3	Glioblastoma (Glioblastoma Multiforme) 01/2018 - 12/2012
2	Breast Neoplasms (Breast Cancer) 12/2023 - 11/2023
2	Lung Neoplasms (Lung Cancer) 01/2022 - 08/2012
2	Epilepsy (Aura) 10/2018 - 01/2018
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2013 - 08/2012
1	Triple Negative Breast Neoplasms 12/2023
1	Ataxia Telangiectasia (Louis Bar Syndrome) 12/2023
1	Disease Progression 12/2023
1	Osteosarcoma (Osteogenic Sarcoma) 06/2022
1	Human Influenza (Influenza) 01/2022
1	Infections 01/2022
1	Postpartum Depression (Post-Natal Depression) 01/2022
1	Otitis Media with Effusion 09/2021
1	Hearing Loss (Hearing Impairment) 09/2021
1	HIV Infections (HIV Infection) 01/2021
1	Substance-Related Disorders (Drug Abuse) 01/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020
1	Drug-Related Side Effects and Adverse Reactions 09/2019
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2019
1	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2018
1	Ischemia 04/2015
1	Communicable Diseases (Infectious Diseases) 01/2014
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2013
1	Insulin Resistance 07/2013
1	Carcinogenesis 12/2012
1	Glioma (Gliomas) 12/2012

Drug/Important Bio-Agent (IBA)

7	Proteins (Proteins, Gene)FDA Link 12/2023 - 12/2012
2	CytokinesIBA 01/2022 - 01/2014
2	PhosphotyrosineIBA 01/2018 - 04/2015
2	Phosphotransferases (Kinase)IBA 01/2018 - 08/2012
2	Tyrosine (L-Tyrosine)FDA Link 04/2013 - 12/2012
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2013 - 08/2012
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 01/2024
1	olaparibIBA 12/2023
1	ceralasertibIBA 12/2023
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2023
1	Fulvestrant (Faslodex)FDA Link 11/2023
1	Hormones (Hormone)IBA 11/2023
1	SeleniumIBA 12/2022
1	Biomarkers (Surrogate Marker)IBA 06/2022
1	mifamurtideIBA 06/2022
1	Antiviral Agents (Antivirals)IBA 01/2022
1	AntioxidantsIBA 01/2022
1	Interferon Type IIBA 01/2022
1	Tuberculin (PPD)IBA 01/2022
1	Superoxide DismutaseIBA 01/2022
1	E 10 (E-10)IBA 01/2022
1	Maraviroc FDA Link 01/2021
1	Dopamine (Intropin)FDA LinkGeneric 01/2021
1	ElementsIBA 01/2020
1	Long Noncoding RNAIBA 01/2020
1	TESIBA 01/2020
1	Nicotinamide MononucleotideIBA 01/2019
1	NAD (NADH)IBA 01/2019
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2018
1	PhosphoproteinsIBA 01/2016
1	Growth Factor ReceptorsIBA 01/2014
1	Non-Receptor Type 1 Protein Tyrosine PhosphataseIBA 07/2013
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 04/2013
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 04/2013
1	Epidermal Growth Factor (EGF)IBA 04/2013
1	ErbB Receptors (EGF Receptor)IBA 04/2013
1	Carrier Proteins (Binding Protein)IBA 12/2012
1	epidermal growth factor receptor VIIIIBA 12/2012
1	major vault proteinIBA 12/2012
1	Carbonic Anhydrase IIIIBA 12/2012

Therapy/Procedure

3	Therapeutics 01/2024 - 01/2016
3	Polypharmacy 09/2019 - 01/2018
1	Middle Ear Ventilation (Tympanostomy) 09/2021
1	Drug Therapy (Chemotherapy) 01/2018
1	Immunomodulation 01/2014